Bausch Health Companies Inc. (BHC) News
Filter BHC News Items
BHC News Results
|Loading, please wait...|
BHC News Highlights
- For BHC, its 30 day story count is now at 15.
- Over the past 28 days, BHC's stories per day has been in a clear downtrend, falling by about 0.07 per 2 days.
- The most mentioned tickers in articles about BHC are TEVA, AVAH and EHC.
Latest BHC News From Around the Web
Below are the latest news stories about BAUSCH HEALTH COMPANIES INC that investors may wish to consider to help them evaluate BHC as an investment opportunity.
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders ...
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
Here is how Bausch Health (BHC) and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have performed compared to their sector so far this year.
Peter Hodson: Looking for clues on where these companies went wrong could help future stock picks
The average of price targets set by Wall Street analysts indicates a potential upside of 38.3% in Bausch (BHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$25.50 Current share...
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.
Here is how Aveanna Healthcare (AVAH) and Bausch Health (BHC) have performed compared to their sector so far this year.
Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.
UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.